MX9304611A - Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion. - Google Patents

Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion.

Info

Publication number
MX9304611A
MX9304611A MX9304611A MX9304611A MX9304611A MX 9304611 A MX9304611 A MX 9304611A MX 9304611 A MX9304611 A MX 9304611A MX 9304611 A MX9304611 A MX 9304611A MX 9304611 A MX9304611 A MX 9304611A
Authority
MX
Mexico
Prior art keywords
crystalline hydrate
triazolyltiomethyl
clohydrate
cephalosporine
preparation
Prior art date
Application number
MX9304611A
Other languages
English (en)
Inventor
Hisanori Takahashi
Yutaka Ide
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX9304611A publication Critical patent/MX9304611A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe el clorhidrato del ácido 7-beta-[(Z)-(2-amino-4-tiazolil)-2-hidroxiiminoace tamino]-3-cefem-4-carboxílico y su hidrato cristalino, los cuales tienen una potente actividad antibiótica y son de baja toxicidad y farmacéuticamente estables, con lo cual son útiles como ingredientes activo de formulaciones antibióticas clínicamente útiles, y la producción de los mismos.
MX9304611A 1992-07-31 1993-07-30 Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion. MX9304611A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20496592 1992-07-31

Publications (1)

Publication Number Publication Date
MX9304611A true MX9304611A (es) 1994-02-28

Family

ID=16499234

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304611A MX9304611A (es) 1992-07-31 1993-07-30 Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion.

Country Status (23)

Country Link
US (1) US5407929A (es)
EP (1) EP0581552B1 (es)
KR (1) KR100245938B1 (es)
CN (1) CN1037683C (es)
AT (1) ATE165360T1 (es)
AU (1) AU657866B2 (es)
BR (1) BR9303235A (es)
CA (1) CA2101502A1 (es)
DE (1) DE69318077T2 (es)
ES (1) ES2115725T3 (es)
FI (1) FI933391L (es)
GR (1) GR3026699T3 (es)
HU (1) HU219637B (es)
IL (1) IL106516A (es)
MX (1) MX9304611A (es)
NO (1) NO303734B1 (es)
NZ (1) NZ248285A (es)
PH (1) PH30109A (es)
PL (2) PL172830B1 (es)
RU (1) RU2118959C1 (es)
TW (1) TW307769B (es)
UA (1) UA37181C2 (es)
ZA (1) ZA935529B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1757606E (pt) * 2001-02-24 2009-05-26 Boehringer Ingelheim Pharma Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
AT413282B (de) * 2002-02-01 2006-01-15 Sandoz Ag Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl)
KR20030076759A (ko) * 2002-03-21 2003-09-29 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
PL376557A1 (pl) 2003-02-12 2006-01-09 Ciba Specialty Chemicals Holding Inc. Postacie krystaliczne pitawastatyny wapnia
CA2519272C (en) 2003-03-27 2010-06-08 Basilea Pharmaceutica Ag Cephalosporin in crystalline form
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
US20110112069A1 (en) * 2007-08-17 2011-05-12 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
KR101791403B1 (ko) * 2008-08-15 2017-10-30 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ-관련 질환의 치료에 사용하기 위한 퓨린 유도체
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
MX364651B (es) 2009-11-27 2019-05-03 Boehringer Ingelheim Int Gmbh Star Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK3517539T3 (en) 2011-07-15 2023-01-16 Boehringer Ingelheim Int Farmaceutiske sammensætninger til behandling af type i og type ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES475573A1 (es) * 1977-07-12 1980-01-16 Fujisawa Pharmaceutical Co Un procedimiento para preparar nuevos compuestos de cefem
IE65926B1 (en) * 1990-07-19 1995-11-29 Shionogi & Co Thioalkylthio cephalosporin derivatives

Also Published As

Publication number Publication date
HUT68602A (en) 1995-06-28
IL106516A0 (en) 1993-11-15
ES2115725T3 (es) 1998-07-01
NZ248285A (en) 1994-07-26
HU9302194D0 (en) 1993-10-28
CN1089948A (zh) 1994-07-27
EP0581552B1 (en) 1998-04-22
RU2118959C1 (ru) 1998-09-20
ZA935529B (en) 1994-02-24
EP0581552A3 (en) 1994-06-01
DE69318077T2 (de) 1998-10-29
BR9303235A (pt) 1994-03-01
KR940005636A (ko) 1994-03-22
HU219637B (hu) 2001-06-28
FI933391A7 (fi) 1994-02-01
IL106516A (en) 1998-06-15
GR3026699T3 (en) 1998-07-31
NO303734B1 (no) 1998-08-24
PL172835B1 (pl) 1997-12-31
UA37181C2 (uk) 2001-05-15
TW307769B (es) 1997-06-11
DE69318077D1 (de) 1998-05-28
NO932745D0 (no) 1993-07-30
ATE165360T1 (de) 1998-05-15
FI933391L (fi) 1994-02-01
AU657866B2 (en) 1995-03-23
KR100245938B1 (ko) 2000-04-01
EP0581552A2 (en) 1994-02-02
NO932745L (no) 1994-02-01
PL172830B1 (pl) 1997-12-31
AU4422793A (en) 1994-02-03
US5407929A (en) 1995-04-18
PH30109A (en) 1996-12-27
PL299870A1 (en) 1994-02-07
FI933391A0 (fi) 1993-07-29
CN1037683C (zh) 1998-03-11
CA2101502A1 (en) 1994-02-01

Similar Documents

Publication Publication Date Title
MX9304611A (es) Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion.
PT91246A (pt) Processo para a preparacao de composicoes farmaceuticas para administracao endovenosa, contendo ciclosporina como ingrediente activo
MY120842A (en) 1,4-benzothiazepine-1, 1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use.
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
IT1201149B (it) Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
MEP10408A (en) Platinum derivative pharmaceutical formulations
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
CA2098076A1 (en) Imidate prodrugs of pharmaceutically useful anticonvulsant sulfamates
AU2001293233A1 (en) Aza heterocyclic derivatives and their therapeutic use
EP0937459A3 (en) Pharmaceutical compositions for the treatment of ischemic brain damage
BR0313162A (pt) Composto, processo para preparar o mesmo, e, composição farmacêutica
AR026064A1 (es) Compuestos de oxabispidina, formulacion farmaceutica, uso de estos compuestos para la manufactura de medicamentos, proceso para la preparacion de estos compuestos, e intermediarios.
ES2054949T3 (es) Precursores de dopamina.
IT1263089B (it) Composti pirrol-amidinici, processi di preparazione e composizioni farmaceutiche che li contengono.
IT1271456B (it) Composti pirrol-amidinici, e loro sali farmaceuticamente accettabili, processi di preparazione e composizioni farmaceutiche che li contengono
JP2000159790A5 (es)
ES2057225T3 (es) Una composicion para la preparacion de una vitamina d3 activa en forma de dosificacion y su procedimiento de preparacion.
DE69915487D1 (de) Erythromycin-derivate mit antibiotischer wirkung
ES2090083T3 (es) Derivados de cefalosporina, procedimiento para su preparacion y composicion antimicrobiana que contiene estos derivados.
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
IE37250B1 (en) Diazepine derivatives and processes for their production
AR026451A1 (es) Compuestos heterociclicos sililados
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas